Drug: Folotyn
Indication: Relapsed peripheral T-cell lymphoma
Company: Allos Therapeutics
Date Approved: Sept. 24
Scoop: Folotyn is the first and only drug approved for PTCL, a rare form of blood cancer that has a poor prognosis and a high relapse rate. An expert panel backed the treatment despite questions about the drugmaker's clinical data and the safety profile. Allos has faced some criticism of the drug due to it's $30,000-per-month price tag, but the company says it's priced similarly to other rare disease drugs and adds that patients only receive Folotyn for a few months.
No comments:
Post a Comment